Aldeyra Therapeutics (STU:137) E10: €-1.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:137 Aldeyra Therapeutics Inc STU:137
30 GF Score
Price €1.35
! 1 Warning Sign
View Full Analysis

What is Aldeyra Therapeutics E10?

Aldeyra Therapeutics STU:137 30 E10 is €-1.27 as of Jun. 2026. GuruFocus rates STU:137 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aldeyra Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.078. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.27 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 34.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Aldeyra Therapeutics was 34.80% per year. The lowest was 34.80% per year. And the median was 34.80% per year.

As of today (2026-08-18), Aldeyra Therapeutics's current stock price is €1.35. Aldeyra Therapeutics's E10 for the quarter that ended in Jun. 2026 was €-1.27. Aldeyra Therapeutics's Shiller PE Ratio of today is .


Aldeyra Therapeutics  (STU:137) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aldeyra Therapeutics E10 Related Terms


Aldeyra Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics E10 Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -5.22 -1.66 -1.52 -1.28

Aldeyra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -1.33 -1.28 -1.28 -1.27

STU:137 vs NTHI, BMEA, PTHS: E10 Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Shiller PE Ratio falls into.


STU:137
30GF Score
Aldeyra Therapeutics Inc STU:137
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aldeyra Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.078/333.9520*333.9520
=-0.078

Current CPI (Jun. 2026) = 333.9520.

Aldeyra Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201609 -0.339 241.428 -0.469
201612 -0.351 241.432 -0.486
201703 -0.346 243.801 -0.474
201706 -0.312 244.955 -0.425
201709 -0.268 246.819 -0.363
201712 -0.304 246.524 -0.412
201803 -0.349 249.554 -0.467
201806 -0.394 251.989 -0.522
201809 -0.446 252.439 -0.590
201812 -0.343 251.233 -0.456
201903 -0.513 254.202 -0.674
201906 -0.434 256.143 -0.566
201909 -0.627 256.759 -0.816
201912 -0.423 256.974 -0.550
202003 -0.308 258.115 -0.398
202006 -0.222 257.797 -0.288
202009 -0.195 260.280 -0.250
202012 -0.247 260.474 -0.317
202103 -0.210 264.877 -0.265
202106 -0.232 271.696 -0.285
202109 -0.230 274.310 -0.280
202112 -0.239 278.802 -0.286
202203 -0.263 287.504 -0.305
202206 -0.284 296.311 -0.320
202209 -0.253 296.808 -0.285
202212 -0.208 296.797 -0.234
202303 -0.252 301.836 -0.279
202306 -0.138 305.109 -0.151
202309 -0.131 307.789 -0.142
202312 -0.073 306.746 -0.079
202403 -0.129 312.332 -0.138
202406 -0.260 314.175 -0.276
202409 -0.225 315.301 -0.238
202412 -0.258 315.605 -0.273
202503 -0.157 319.799 -0.164
202506 -0.139 322.561 -0.144
202509 -0.111 324.800 -0.114
202512 -0.085 324.054 -0.088
202603 -0.052 330.213 -0.053
202606 -0.078 333.952 -0.078

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.27 mean?
Aldeyra Therapeutics (STU:137) has a E10 of €-1.27 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aldeyra Therapeutics and its competitors.
Is Aldeyra Therapeutics' E10 too high?
Aldeyra Therapeutics' current E10 is €-1.27. Overall, Aldeyra Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' E10 compare to NTHI and BMEA?
Aldeyra Therapeutics' E10 of €-1.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current E10 is €-1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (STU:137) has a current E10 of €-1.27. The current E10 is €-1.27. Aldeyra Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Aldeyra Therapeutics (STU:137), the current E10 is €-1.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
30GF Score

Get the complete analysis for STU:137

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.35
Price